Scholarlink

<p>Intratumoral microbiota are implicated in colorectal cancer liver metastasis (CRLM), but their relationships with clinical characteristics and prognosis remain to be explored. Using 5R 16S rRNA gene sequencing method, we analyzed the intratumoral microbiota of patients with colorectal cancer with and without liver metastasis. CRLM patients were classified into three intratumoral microbial community subtypes (IMCSs). These included IMCS1 (sugar metabolism-related liver metastasis with T cell activation, moderate proliferation and invasion, and median disease-free survival (mDFS) of 22 months), IMCS2 (protein metabolism-related liver metastasis with natural killer cell activation, high proliferation and invasion, and mDFS of 12 months), and IMCS3 (lipid metabolism-related liver metastasis with a pauci-immune phenotype, the highest level of proliferation and invasion, and mDFS of 10 months). Our study establishes intratumoral microbiome subtypes as a novel risk stratification strategy for CRLM, facilitating microbiota-directed therapeutic strategies with potential survival benefits.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intratumoral microbial community profiling identifies clinicomolecular and prognostic subtypes of colorectal cancer liver metastasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月15日

查看全文
  • Linhai Yan,
  • Xiaoxia Wei,
  • Fangchao Zhong,
  • Lihua Fu,
  • Haiming Ru,
  • Xianwei Mo,
  • Maosen Huang

摘要

Intratumoral microbiota are implicated in colorectal cancer liver metastasis (CRLM), but their relationships with clinical characteristics and prognosis remain to be explored. Using 5R 16S rRNA gene sequencing method, we analyzed the intratumoral microbiota of patients with colorectal cancer with and without liver metastasis. CRLM patients were classified into three intratumoral microbial community subtypes (IMCSs). These included IMCS1 (sugar metabolism-related liver metastasis with T cell activation, moderate proliferation and invasion, and median disease-free survival (mDFS) of 22 months), IMCS2 (protein metabolism-related liver metastasis with natural killer cell activation, high proliferation and invasion, and mDFS of 12 months), and IMCS3 (lipid metabolism-related liver metastasis with a pauci-immune phenotype, the highest level of proliferation and invasion, and mDFS of 10 months). Our study establishes intratumoral microbiome subtypes as a novel risk stratification strategy for CRLM, facilitating microbiota-directed therapeutic strategies with potential survival benefits.